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Background: Both cervical cancer and human immunodeficiency virus (HIV) are major public health problems in
Sub-Saharan Africa. The objectives of the study were to investigate human papillomavirus (HPV) prevalence
according to age, HIV status and gender.
Methods: Participants were 208 HIV-negative women, 278 HIV-positive women, 325 HIV-negative men and 161
HIV-positive men between the ages of 18–66 years. HPV types were determined in cervical and penile cells by
Roche Linear Array HPV genotyping assay.
Results: HPV prevalence was 36.7 % (76/207; 95 % confidence intervals (CI): 30.4–43.4 %) in HIV-negative women,
with the highest prevalence of 61.0 % (25/41; 95 % CI: 45.7–74.4 %) in women aged 18–25 years. HPV prevalence
was 74.0 % (205/277; 95 % CI: 68.5–78.8 %) in HIV-positive women, with the highest prevalence of 86.4 %
(38/44; 95 % CI: 72.9–94.0 %) in women aged 18–25 years. HPV prevalence was found to decrease with
increasing age in HIV-negative women (P = 0.0007), but not in HIV-positive women (P = 0.898). HPV prevalence was
50.8 % (159/313; 95 % CI: 45.3–56.3 %) in HIV-negative men, with the highest prevalence of 77.0 % (27/35; 95 % CI:
60.7–88.2 %) in men aged 18–25 years. HPV prevalence was 76.6 % (121/158; 95 % CI: 69.2–82.9 %) in HIV-positive
men, with the highest prevalence of 87.5 % (7/8; 95 % CI: 50.8–99.9 %) in men 18–25 years of age. HPV prevalence
was found to decrease with increasing age in HIV-negative men (P = 0.004), but not in HIV-positive men
(P = 0.385). HIV-positive women had a significantly higher prevalence of one or more HPV type(s) in the
bivalent (HPV-16/18: 20 % 55/277, 9 % 12/207; P <0.001), quadrivalent (HPV-6/11/16/18: 26 % 71/277, 12 % 24/207;
P = 0.001) and nonavalent vaccine (HPV-6/11/16/18/31/33/52/56/58: 65 % 181/277, 24 % 50/207; P <0.001) compared
to HIV-negative women. Similar observation were observed in men for bivalent (20 % 32/158, 10 % 30/313; P = 0.001),
quadrivalent (35 % 56/158, 13 % 41/313; P <0.001) and nonavalent vaccine (75 % 119/158, 28 % 87/313; P <0.001).
Conclusions: This study demonstrated high HPV prevalence among HIV-positive women and men in all age
groups. The high prevalence of HPV types found in bivalent, quadrivalent and nonavalent vaccines in South African
HIV-positive and HIV-negative women and men demonstrate that this population will greatly benefit from current
HPV vaccines.
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Worldwide 35.3 million people were living with human
immunodeficiency virus (HIV) in 2012; 25 million in
sub-Saharan Africa and 6.3 million in South Africa
[1, 2]. HIV prevalence is higher in women than men.
The peak in women is between 25 and 29 years
while in men it is between 30 and 34 years of age
[1–3]. In South Africa, women are more likely to have
sexual partners who are 4 years older than themselves
[4–7]. The median age at first sex in South African
women ranges between 16 and 18 years while in men
it ranges between 17 and 19 years of age [6, 8]. In a
worldwide meta-analysis Africa was found to have the
highest human papillomavirus (HPV) prevalence in
women with normal cytology [9, 10]. Sub-Saharan Africa
has the highest burden of HIV and cervical cancer and the
epidemic of cervical cancer and HIV infection are major
public health problems [2, 11].
Both HIV and HPV are sexually transmitted, with
HPV being more infectious than HIV [12]. The preva-
lence of HIV and HPV is significantly higher among
women and men with high-risk sexual behaviour [10].
HIV infection is significantly associated with a higher in-
cidence of HPV, prevalence of HPV and persistence in
women and men [13–15]. HIV-positive individuals are
more likely to have multiple HPV infection and HPV
viral load compared to their HIV-negative counterparts
[16–19]. HPV-associated cancers occur more fre-
quently in HIV-positive than in HIV-negative individuals
[20, 21]. There is increasing evidence that HPV is associ-
ated with a two-three fold higher risk of HIV acquisition
in both women and men [12, 22–30]. There are three
HPV vaccines available, namely, bivalent vaccine
(Cervarix®, GlaxoSmithKline) protecting against HPV
16/18, quadrivalent vaccine (Gardasil®, Merck), protecting
against HPV 6/11/16/18 and nonavalent vaccine (Merck)
protecting against HPV-6/11/16/18/31/33/52/56/58). These
vaccines prevent infection and disease related to types they
are targeting [31–36]. In March 2014, South Africa intro-
duced vaccination with Cervarix® against HPV in schools,
aiming to cover around 520 000 girls.
HPV prevalence decreases with increasing age in
women [9, 37]. However, among older women inconsist-
ent trends in HPV prevalence are observed, with some
studies reporting a decrease or plateau in HPV preva-
lence while others report an increased HPV prevalence
in older women [37]. HPV prevalence in women differs
by country, region within the country and population
group and this is likely to be due to the varying preva-
lence of high risk sexual behaviour worldwide [38]. HPV
is acquired soon after sexual debut and the peak preva-
lence is observed in young women. The age distribution
of HPV prevalence in African women is characterised by
a U shape with high HPV prevalence in young and olderages [9, 38]. In sub-Saharan Africa genital HPV is re-
ported to be very common in men [39, 40] and HPV
prevalence does not decrease with age [41, 42]. The aim
of this study is to demonstrate HPV prevalence, strati-
fied by age and HIV status in women and men recruited
from the same community.
Methods
Study population and specimen collection
The Research Ethics Committee of the University of
Cape Town approved the study (reference: 258/2006)
and written informed consent was obtained. Study
participants were recruited from the Manyanani clinic,
Empilisweni Centre, Gugulethu, Cape Town, South Africa
between 2006 and 2009. Empilisweni is a wellness centre
where HIV-related research is conducted. Individuals were
recruited through clinics, bus stops and taxi ranks and eli-
gible individuals were asked to come to Manyanani clinic.
The study participants had to have had penetrative sexual
intercourse with the partner of the opposite sex in the pre-
vious month to be enrolled in the study. Participation to
the study was completely voluntary.
Cervical samples were collected by clinician using
Digene cervical samplers. Clinicians collected penile
samples by swabbing the penile shaft, glans, and foreskin
with a dry Digene swab. Genital samples were stored in
Digene transport medium at −80 °C until analysed.
Study participants included 208 HIV-negative women,
278 HIV-positive women, 325 HIV-negative men and
161 HIV-positive men between the ages of 18 and
66 years. Cervical and penile samples were collected and
stored as described by Mbulawa et al., [43].
HPV genotyping
DNA was extracted by a MagNA Pure Compact (Roche)
using the MagNA Pure Compact Nucleic Acid Isolation
Kit (Roche). HPV genotyping was performed using the
Roche Linear Array HPV genotyping test which identi-
fies 37 different HPV genotypes. High-risk (HR) HPV
types included HPV−16, −18, −31, −33, −35, −39, −45,
−51, −52, −56, −58 and −59; probably or possible HR-
HPV types included HPV−26, −53, −66, −67, −68, −70,
−73 and −82; and low-risk (LR) HPV types HPV-6, −11,
−40, 42, −54, −55, −61, −62, −64, −69, −71, −72, −81,
−83, −84, −89 (HPV-CP6108) and –IS39 [44].
Statistical analyses
Multiple HPV infection was defined as infection where
two or more HPV types were detected. Cases with
multiple infections were counted more than once
when determining LR-HPV, HR-HPV, bivalent, quadriva-
lent or nonavalent prevalence. Statistical analysis was per-
formed using chi-squared and chi-squared for trends
(GraphPad prism 5). The 95 % confidence intervals of the
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(GraphPad Prism). Differences were considered to be sta-
tistically significant when P-values were <0.05.
Results
HPV prevalence in women according to age and HIV status
Demographic data are presented in Table 1. The median
age was 37 years (18–66 years) for HIV-negative women;
32 years (18–65 years) for HIV-positive women; 38 years
(19–67 years) for HIV-negative men and 36 years (22–
64 years) for HIV-positive men. Table 2 presents the
prevalence of any HPV, HR-HPV, probable HR-HPV,
LR-HPV, multiple HPV infection and single HPV infec-
tion stratified by age and HIV status in women. OverallTable 1 The demographic data of study participants
HIV-negative women, N = 208 HIV-positive wom
Median age (range) 37 years (18–66 years) 32 years (18–65 y
18–25 years N = 41, median: 22 years N = 44, median: 2
26–35 years N = 59, median: 30 years N = 130, median:
36–45 years N = 64, median: 40 years N = 71, median: 3
46–66 years N = 44, median: 49 years N = 33, median: 4
CD4 count
≥350 ml−1 .. 139 (50 %)
<350 ml−1 .. 137 (49.3 %)
Missing .. 2 (0.7 %)
Age at first sex
<16 years 28 (63.9 %) 49 (17.6 %)
16–18 years 123 (59.1 %) 171 (61.5 %)
>18 years 55 (26.4 %) 57 (20.5 %)
Missing 2 (1.0 %) 1 (0.4 %)
Smoking
Never 133 (63.9 %) 182 (65.5 %)
Previously 13 (6.3 %) 28 (10.1 %)
Current 62 (29.8 %) 68 (24.5 %)
Missing 0 (0.0 %) 0 (0.0 %)
Lifetime number of sexual partners
1–3 137 (65.9 %) 134 (48.2 %)
4–6 51 (24.5 %) 106 (38.1 %)
≥7 17 (8.2 %) 37 (13.3 %)
Missing 3 (1.4 %) 1 (0.4 %)
Cervical cytology
Normal 157 (75.5 %) 167 (60.1 %)
ASCUS 19 (9.1 %) 23 (8.3 %)
LSIL 17 (8.2 %) 63 (22.7 %)
HSIL 2 (1.0 %) 10 (3.6 %)
Inadequate 13 (6.2 %) 14 (5.0 %)
Missing 0 (0.0 %) 1 (0.4 %)
ASCUS atypical squamous cell of undetermined significance, LSIL low grade squamoHPV prevalence in women was 58.1 % (281/484; 95 %
CI: 53.6–62.4 %), with the highest prevalence of 74.1 %
(63/85; 95 % CI: 63.9–82.3 %) observed in women 18–25
years of age and lowest prevalence of 50.0 % (67/134;
95 % CI: 41.7–58.4 %) in women 36–45 years of age.
Age group 18–25 years were found to have significantly
higher HPV prevalence compared to 26–35 years
(74.1 % compared to 59.0 %, P = 0.017); to 36–45 years
(74.1 % compared to 50.0 %, P = 0.0004) and to 46–66
years (74.1 % compared to 51.9 %, P = 0.0035). HPV
prevalence was found to decrease with increasing age in
women (P = 0.0032). The prevalence of multiple infec-
tions was 34.3 % (166/484) and of single infection was
23.8 % (115/484; Table 2).en, N = 278 HIV-negative men, N = 325 HIV-positive men, N = 161
ears) 38 years (19–67 years) 36 years (22–64 years)
3 years N = 35, median: 24 years N = 8, median: 23 years
30 years N = 99, median: 31 years N = 64, median: 31 years
9 years N = 105, median: 40 years N = 67, median: 39 years
9 years N = 86, median: 53 years N = 22, median: 52 years
.. 76 (47.2 %)
.. 81 (50.3 %)
.. 4 (2.5 %)
87 (26.8 %) 40 (24.8 %)
163 (50.2 %) 94 (58.4 %)
71 (21.8 %) 26 (16.2 %)
4 (1.2 %) 1 (0.6 %)
48 (26.8 %) 31 (19.3 %)
45 (13.8 %) 26 (16.1 %)
228 (70.2 %) 104 (64.6 %)
4 (1.2 %) 0 (0 %)
94 (28.9 %) 39 (24.2 %)
91 (28.0 %) 38 (23.6 %)
136 (41.8 %) 82 (50.9 %)
4 (1.2 %) 2 (1.2 %)
us intraepithelial lesion, HSIL high grade squamous intraepithelial lesion
Table 2 Human papillomavirus (HPV) by age and human immunodeficiency (HIV) status in women
All women HIV-positive women HIV-negative women P-valuea
N = 484 N = 277 N = 207
Any HPV
All women 58.1 % (281/484) 74.0 % (205/277) 36.7 % (76/207) <0.0001
18–25 years 74.1 % (63/85) 86.4 % (38/44) 61.0 % (25/41) 0.008
26–35 years 59.0 % (111/188) 68.2 % (88/129) 39.0 % (23/59) 0.0002
36–45 years 50.0 % (67/134) 73.2 % (52/71) 23.8 % (15/63) <0.0001
46–66 years 51.9 % (40/77) 81.8 % (27/33) 29.5 % (13/44) <0.0001
Multiple HPV infections
All women 34.3 % (166/484) 49.8 % (138/277) 13.5 % (28/207) <0.0001
18–25 years 47.1 % (40/85) 61.4 % (27/44) 31.7 % (13/41) 0.007
26–35 years 34.6 % (65/188) 45.0 % (58/129) 11.9 % (7/59) <0.0001
36–45 years 30.6 % (41/134) 49.3 % (35/71) 9.5 % (6/63) <0.0001
46–66 years 26.0 % (20/77) 54.5 % (18/33) 4.5 % (2/44) <0.0001
Single HPV infection
All women 23.8 % (115/484) 24.2 % (67/277) 23.2 % (48/207) 0.800
18–25 years 27.1 % (23/85) 25.0 % (11/44) 29.3 % (12/41) 0.664
26–35 years 24.5 % (46/188) 23.3 % (30/129) 27.1 % (16/59) 0.570
36–45 years 19.4 % (26/134) 23.9 % (17/71) 14.3 % (9/63) 0.161
46–66 years 26.0 % (20/77) 27.3 % (9/33) 25.0 % (11/44) 0.828
HR-HPV
All women 39.5 % (191/484) 52.0 % (144/277) 22.7 % (47/207) <0.0001
18–25 years 54.1 % (46/85) 72.7 % (32/44) 34.1 % (14/41) 0.0004
26–35 years 37.2 % (70/188) 40.3 % (52/129) 30.5 % (18/59) 0.199
36–45 years 41.8 % (56/134) 64.8 % (46/71) 15.9 % (10/63) <0.0001
46–66 years 24.7 % (19/77) 42.4 % (14/33) 11.4 % (5/44) 0.002
Probable HR-HPV
All women 21.1 % (102/484) 30.7 % (85/277) 8.2 % (17/207) <0.0001
18–25 years 25.9 % (22/85) 34.1 % (15/44) 17.1 % (7/41) 0.080
26–35 years 27.1 % (51/188) 37.2 % (48/129) 5.1 % (3/59) <0.0001
36–45 years 15.7 % (21/134) 22.5 % (16/71) 7.9 % (5/63) 0.02
46–66 years 10.4 % (8/77) 18.2 % (6/33) 4.5 % (2/44) 0.055
LR-HPV
All women 34.5 % (167/484) 49.8 % (138/277) 14.0 % (29/207) <0.0001
18–25 years 44.7 % (38/85) 63.6 % (28/44) 24.4 % (10/41) 0.0003
26–35 years 36.7 % (69/188) 48.1 % (62/129) 11.9 % (7/59) <0.0001
36–45 years 26.9 % (36/134) 43.7 % (31/71) 7.9 % (5/63) <0.0001
46–66 years 31.2 % (24/77) 51.5 % (17/33) 15.9 % (7/44) 0.0006
Number of infection will not always add up because participants with multiple infection were sometimes counted more than once. acompares HIV-positive and
HIV-negative women (chi-squared test)
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78.8 %) in HIV-positive women, with the highest preva-
lence of 86.4 % (38/44; 95 % CI: 72.9–94.0 %) in women
18–25 years of age and lowest prevalence of 68.2 % (88/
129; 95 % CI: 60.0–75.6 %) in women 26–35 years of age.
HIV-positive age group 18–25 years were found to havesignificantly higher HPV prevalence compared to 26–35
years (86.4 % compared to 68.2 %, P = 0.02); but not 36–
45 years (86.4 % compared to 73.2 %, P = 0.1) and 46–66
years age group (86.4 % compared to 81.8 %, P = 0.59;
Table 2). Among HIV-positive women, HPV prevalence
did not decrease with increasing age (P = 0.898).
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30.4–43.5 %) in HIV-negative women, with the high-
est prevalence of 61.0 % (25/41; 95 % CI: 45.7–
74.4 %) in women 18–25 years of age and lowest
prevalence of 23.8 % (15/63; 95 % CI: 14.9–35.7 %) in
women 36–45 years of age. HPV prevalence was
found to be significantly higher in age group 18–25
years compared to 26–35 years (61.0 % compared to
39.0 %, P = 0.03); to 36–45 years (61.0 % compared to
23.8 %, P = 0.0002) and to 46–66 years (61.0 % compared
to 29.5 %, P = 0.004; Table 2). HPV prevalence was found
to decrease with increasing age in HIV-negative women
(P = 0.0007). HIV-positive women were found to have
significantly higher HPV prevalence compared to HIV-
negative women in all age group (Table 2).
A higher proportion of detected HPV types in multiple
infections than single infection were observed. The dis-
tribution of multiple infections (range: 2–14 HPV geno-
types) is shown in Fig. 1a for HIV-positive women and
Fig. 1b for HIV-negative women. Multiple HPV infec-
tions in HIV-negative women were more likely to be 2
HPV types while in HIV-positive women the distribution












































Fig. 1 Distribution of multiple HPV genotype infections in HIV-positive (a)HPV prevalence in men according to age and HIV status
Table 3 presents prevalence of any HPV, HR-HPV, prob-
able HR-HPV, LR-HPV, multiple HPV infection and sin-
gle HPV infection stratified by age and HIV status in
men. HPV prevalence in men was 59.4 % (280/471; 95 %
CI: 55.0–63.8 %) with the highest prevalence of 79.1 %
(34/43; 95 % CI: 64.6–88.8 %) in men 18–25 years of
age and lowest prevalence of 47.6 % (50/105; 95 % CI:
38.3–57.1 %) in age. HPV prevalence was found to be
significantly higher in age group 18–25 years compared
to 26–35 years (79.1 % compared to 60.9 %, P = 0.03); to
36–45 years (79.1 % compared to 60.5 %, P = 0.02) and to
46–66 years (79.1 % compared to 47.9 %, P = 0.0005).
HPV prevalence was found to decrease with increasing
age in men (P = 0.0012). The prevalence of multiple infec-
tions was 41.0 % (193/471) and of single infection was
18.5 % (87/471) in men.
HPV prevalence was 76.6 % (121/158; 95 % CI: 69.4–
82.5 %) in HIV-positive men, with the highest prevalence
of 87.5 % (7/8; 95 % CI: 50.8–99.9 %) in men 18–25
years of age and lowest prevalence of 71.4 % (15/21;
95 % CI: 49.8–86.4 %) in men 46–66 years of age. HPV












and HIV-negative (b) women
Table 3 Human papillomavirus (HPV) by age and human immunodeficiency (HIV) status in men
All men HIV-positive men HIV-negative men P-valuea
N = 471 N = 158 N = 313
Any HPV
All men 59.4 % (280/471) 76.6 % (121/158) 50.8 % (159/313) <0.0001
18–25 years 79.1 % (34/43) 87.5 % (7/8) 77.1 % (27/35) 0.535
26–35 years 60.9 % (95/156) 77.8 % (49/63) 49.5 % (46/93) 0.0004
36–45 years 60.5 % (101/167) 75.8 % (50/66) 50.5 % (51/101) 0.001
46–66 years 47.6 % (50/105) 71.4 % (15/21) 41.7 % (35/84) 0.015
Multiple HPV infections
All men 41.0 % (193/471) 62.7 % (99/158) 30.0 % (94/313) <0.0001
18–25 years 55.8 % (24/43) 87.5 % (7/8) 48.6 % (17/35) 0.050
26–35 years 44.2 % (69/156) 68.3 % (43/63) 28.0 % (26/93) <0.0001
36–45 years 41.3 % (69/167) 59.1 % (39/66) 29.7 % (30/101) 0.0002
46–66 years 29.5 % (31/105) 47.6 % (10/21) 25.0 % (21/84) 0.041
Single HPV infection
All men 18.5 % (87/471) 13.9 % (22/158) 20.8 % (65/313) 0.071
18–25 years 23.3 % (10/43) 0.0 % (0/8) 28.6 % (10/35) …
26–35 years 35.9 % (56/156) 9.5 % (6/63) 21.5 % (20/93) 0.050
36–45 years 19.2 % (32/167) 16.7 % (11/66) 20.8 % (21/101) 0.511
46–66 years 18.1 % (19/105) 23.8 % (5/21) 16.7 % (14/84) 0.453
HR-HPV
All men 19.7 % (93/471) 54.4 % (86/158) 22.4 % (70/313) <0.0001
18–25 years 48.8 % (21/43) 75.0 % (6/8) 42.9 % (15/35) 0.109
26–35 years 39.1 % (61/156) 61.9 % (39/63) 23.7 % (22/93) <0.0001
36–45 years 32.9 % (55/167) 50.0 % (33/66) 21.8 % (22/101) 0.0002
46–66 years 21.0 % (22/105) 28.6 % (6/21) 19.0 % (16/84) 0.343
Probable HR-HPV
All men 16.1 % (76/471) 54.4 % (86/158) 20.8 % (65/313) <0.0001
18–25 years 41.9 % (18/43) 62.5 % (5/8) 37.1 % (13/35) 0.201
26–35 years 28.2 % (44/156) 44.4 % (28/63) 17.2 % (16/93) 0.0002
36–45 years 29.9 % (50/167) 31.8 % (21/66) 28.7 % (29/101) 0.671
46–66 years 15.2 % (16/105) 42.9 % (9/21) 8.3 % (7/84) <0.0001
LR-HPV
All men 29.5 % (139/471) 63.9 % (101/158) 33.2 % (104/313) <0.0001
18–25 years 53.5 % (23/43) 75.0 % (6/8) 48.6 % (17/35) 0.187
26–35 years 37.8 % (59/156) 66.7 % (42/63) 18.3 % (17/93) <0.0001
36–45 years 47.9 % (80/167) 59.1 % (39/66) 40.6 % (41/101) 0.020
46–66 years 41.0 % (43/105) 66.7 % (14/21) 34.5 % (29/84) 0.008
Number of infection will not always add up because participants with multiple infections were sometimes counted more than once. acompares HIV-positive and
HIV-negative men (chi-squared test)
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compared to 77.8 %, P = 0.54); to 36–45 years (87.5 %
compared to 75.8 %, P = 0.47) and to 46–66 years
(87.5 % compared to 71.4 %, P = 0.39). HPV prevalence
was not found to decrease with increasing age in HIV-
positive men (P = 0.385); however, overall HPV prevalenceand prevalence of multiple infections were high across all
age groups (Table 3).
HPV prevalence was 50.8 % (159/313; 95 % CI:
45.3–56.3 %) in HIV-negative men, with the highest
prevalence of 77.1 % (27/35; 95 % CI: 60.7–88.2 %) in men
18–25 years of age and lowest prevalence of 41.7 %
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age. HPV prevalence was found to be significantly
higher in age group 18–25 years compared to 26–35
years (77.1 % compared to 49.5 %, P = 0.005); to 36–45
years (77.1 % compared to 50.5 %, P = 0.006) and to 46–66
years (77.1 % compared to 41.7 %, P = 0.0004). HPV
prevalence was found to decrease with increasing age in
HIV-negative men (P = 0.004). HIV-positive men were
found to have significantly higher HPV prevalence com-
pared to HIV-negative men in all age groups except for
18–25 years age group (Table 3).
A higher proportion of detected HPV types were ob-
served in multiple infections than single infection. The
distribution of multiple infections (range: 2–13 HPV ge-
notypes) is shown in Fig. 2a for HIV-positive men and
Fig. 2b for HIV-negative men. Multiple HPV infections
in HIV-negative men were more likely to be 2 HPV
types while in HIV-positive men the distribution of mul-












































Fig. 2 Distribution of multiple HPV genotype infections in HIV-positive (a)Prevalence of HPV types targeted by current HPV
vaccines
HIV-positive women had a significantly higher prevalence
of one or more HPV types found in the bivalent vaccine
(HPV-16/18: 20 % 55/277, 9 % 12/207; P <0.001), in the
quadrivalent vaccine (HPV-6/11/16/18: 26 % 71/277, 12 %
24/207; P = 0.001) and in the nonavalent vaccine (HPV-6/
11/16/18/31/33/52/56/58: 65 % 181/277, 24 % 50/207;
P <0.001) compared to HIV-negative women (Fig. 3).
HIV-positive men also had a significantly higher preva-
lence of one or more types found in the bivalent vaccine
(20 % 32/158, 10 % 30/313; P = 0.001), in the quadrivalent
vaccine (35 % 56/158, 13 % 41/313; P <0.001) and in the
nonavalent vaccine (75 % 119/158, 28 % 87/313; P <0.001)
compared to HIV-negative men (Fig. 3).
Discussion
We previously reported the influence of HIV co-infection












and HIV-negative (b) men
Fig. 3 Prevalence of types targeted by bivalent, quadrivalent and nonavalent HPV vaccines in women and men according to HIV status
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mission in sexual active couples [43, 46, 47]. The current
report further demonstrates prevalence of any HPV type,
LR-HPV, probable HR-HPV, LR-HPV, multiple HPV in-
fections, single HPV infection and prevalence of HPV
types targeted by bivalent, quadrivalent and nonavalent
vaccines in women and men according to HIV status and
age. HPV prevalence data specified by age and HIV status
is important in understanding HPV trends especially in a
country where HIV prevalence is very high. Women and
men participated in this study were recruited as couples
from the same community, a community with high
prevalence of HIV (~30 % amongst pregnant women)
and sexually transmitted infections [48, 49].
Higher prevalence of any HPV type, multiple infec-
tions, and types targeted by bivalent, quadrivalent and
nonavalent vaccines in HIV-positives compared to HIV-
negatives were observed. Generally, in women HPV
prevalence decreased with age and this has been re-
ported elsewhere [9, 38, 50–52]. However, when grouped
according to HIV-status HPV prevalence decreased with
age among HIV-negatives but not among HIV-positive
women. In South African studies, HPV prevalence has
also decreased with increasing age in HIV-negative
women [53, 54] and in women not stratified by HIV sta-
tus [55]. Notably in this study overall HPV prevalence
and multiple infection prevalence remained high in HIV-
positive women across all age groups while it decreased
with age among HIV-negative women. McDonald et al.,
reported higher a HPV prevalence in South African
among HIV-positive women compared to HIV-negative
women in all age groups [54].
The higher prevalence of HPV in older HIV-positive
women could be due to high rate of HPV reactivation as
a result of suppressed immune system and susceptibility
to new infections in HIV-positive women [17, 19]. Ac-
cording to Kjaer et al., HPV prevalence declines withage, even in highly sexually active women such as sex
workers [52]. Some have suggested that older HIV-
positive women are more likely to fail to clear the HPV
infection they acquired at a young age or later, due to
immune senescence [56, 57]. This is important as the
persistence of genital HPV infection is associated with
cervical disease progression [58]. A more intensive cer-
vical screening program is required due to the high HPV
prevalence and multiple infections across all age group
among HIV-positive women.
HIV-prevalence was found to decrease with increasing
age in men, when grouped according to HIV-status, this
was also observed in HIV-negative men but not among
HIV-positive men. In contrast, HPV prevalence in men
has been reported not to vary with age [41, 42], however
these reports were not reported according to HIV status.
High HPV prevalence across age groups or slightly de-
crease as the age increases suggest high rate of persistent
and acquired new HPV infections [42]. We previously
reported high persistent and acquired new infection dur-
ing follow-up among HIV-positive women and men in
this cohort [13].
A high prevalence of infections with multiple HPV
types was observed in HIV-positive women and men.
HPV multiple infections are associated with a higher
rate of persistent HPV infection than single infection
[59]. Munagala et al., showed that persons with infec-
tions with multiple HPV types were more likely to have
larger tumor and a poorer response to cancer treatment
when compared with participants with single HPV infec-
tion [60]. HPV persistent infection is associated with the
development of HPV related cancers in both women
and men; while multiple HPV infection seem to compli-
cate the response to treatment; and cancer prevention
and treatment programs need to take this into consider-
ation [59, 61]. The observations that single infection
were more likely to be HR-HPV types than LR-HPV in
Mbulawa et al. BMC Infectious Diseases  (2015) 15:459 Page 9 of 11women and not in men could be due to the fact that in
women only the cervix was sampled. Jones et al., showed
that LR-HPV were more likely to reside in the vagina
than in the cervix [62]. In men several sites (penile shaft,
glans and foreskin if uncircumcised) were sampled [43].
The prevalence of HPV types targeted by bivalence,
quadrivalent and nonavalent HPV vaccines were found
to be significantly higher among HIV-positives than
HIV-negatives. Giuliano et al., reported a similar preva-
lence of one or more HPV types in quadrivalent (20 %)
and nonavalent (28 %) vaccines in South African HIV-
negative women [53].
The study was limited by the small sample size. Due
to the small sample size the impact of HIV viral load
and CD4 counts on HPV prevalence could not be strati-
fied by age. All participants recruited for the study were
volunteers and therefore not representative of the gen-
eral population. Only participants who were sexually ac-
tive were included and this was based on having had
sexual intercourse in the previous month with a partner
of the opposite sex and this was subject to recall bias. As
this was a cross-sectional study a time sequence could
not be interred.
Conclusion
This study demonstrated high prevalence of HPV and
multiple HPV infection among HIV-positive women
compared to HIV-negative women across all ages. Older
HIV-negative men had a higher prevalence of HPV com-
pared to HIV-negative women of the same age group.
The high prevalence of HPV types targeted by bivalent,
quadrivalent and nonavalent vaccines in South African
HIV-positive and HIV-negative women and men demon-
strate that this population will greatly benefit from
current HPV vaccines. Studies on HPV prevalence
should be stratified by age and HIV status in both
women and men.
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